• Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us
Home
  • Pharma
    • Oncology
    • Vaccines
    • Asia
    • Cell & Gene Therapy
    • Drug Delivery
    • Executives
  • Manufacturing
    • Facilities
    • Recalls
    • Warning Letters
  • Marketing
  • Special Reports
  • Fierce 50
    • Special Report
    • Awards Gala
  • Trending
    • Supply Chain
    • AI and Machine Learning
  • Awards
    • Outsourcing Awards
    • Innovation Awards
    • AI Innovation Awards
    • Pharma Marketing Awards
  • Resources
    • Podcasts
    • Fierce Events
    • Industry Events
    • Webinars
    • Whitepapers
    • Survey
  • Events
  • Subscribe
Home
Subscribe
Hamburger Menu Hamburger Menu
  • Pharma
    • Oncology
    • Vaccines
    • Asia
    • Cell & Gene Therapy
    • Drug Delivery
    • Executives
  • Manufacturing
    • Facilities
    • Recalls
    • Warning Letters
  • Marketing
  • Special Reports
  • Fierce 50
    • Special Report
    • Awards Gala
  • Trending
    • Supply Chain
    • AI and Machine Learning
  • Awards
    • Outsourcing Awards
    • Innovation Awards
    • AI Innovation Awards
    • Pharma Marketing Awards
  • Resources
    • Podcasts
    • Fierce Events
    • Industry Events
    • Webinars
    • Whitepapers
    • Survey
  • Events
  • Subscribe
  • Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us

Myasthenia Gravis

Regeneron
Pharma

Regeneron breaks into gMG with FDA nod for siRNA med Livsayis

Now christened Livsayis to treat adults with the most common form of gMG, Regeneron’s medicine wades into a bustling myasthenia gravis market.
Fraiser Kansteiner Nov 19, 2026 11:16am
Green light double green light approval approvals FDA FDA nod

AZ beefs up myasthenia gravis pedigree with US, EU Klygefa nods

Nov 16, 2026 10:39am
shadow follow leader

Argenx reports Q3 sales bump and a new trial requirement

Oct 23, 2026 11:42am
Close-up of human eye

Roche's Enspryng muscles in on Tepezza's TED turf

Oct 16, 2026 9:26am
UCB sign

UCB partners on meal program for MG patients

Apr 21, 2026 6:26am
Close up shot of the target from a dart game

Argenx's Vyvgart posts ph. 3 win in ocular myasthenia gravis

Feb 26, 2026 11:18am

Home
  • Connect
    • The Team
    • Advertise
    • Marketing Kit
    • Let's Talk
  • Join Us
    • Newsletters
    • Resources
    • RSS Feeds
  • Our Brands
    • Fierce Biotech
    • Fierce Healthcare
    • Fierce Pharma
  • Our Events
    • Life Sciences Events
©2026 Questex LLC All rights reserved.
Terms of use
Privacy Policy
Privacy Settings